Prostate cancer drug shows promise for kidney cancer in new trial

NCT ID NCT06783348

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a radioactive drug, 177Lu-PSMA-617, in people with advanced kidney cancer that has spread and worsened despite standard treatments like immunotherapy and targeted therapy. The drug targets a protein called PSMA found on kidney cancer cells, delivering radiation directly to tumors. About 48 participants who test positive for PSMA will receive up to six doses over six weeks each. The goal is to see if the drug can shrink tumors and control the disease, while monitoring side effects like fatigue, nausea, and blood changes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma Clear-cell metastatic renal cell carcinoma kidney cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Centre Francois Baclesse (CLCC)

    RECRUITING

    Caen, 14076, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Gustave Roussy

    RECRUITING

    Villejuif, 94805, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••